Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
Related Questions
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
Can palliative radiation be used to treat recurrent malignant pleural effusion in NSCLC?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Do you use an LAD constraint in the setting of BID thoracic radiation for SCLC?
Would you offer SBRT as an alternative to surgery for an atypical carcinoid lung tumor?